[go: up one dir, main page]

MX2012002463A - Agonistas del receptor del peptido 1 similar a glucagon (glp-1r) para el tratamiento de trastornos autoinmunitarios. - Google Patents

Agonistas del receptor del peptido 1 similar a glucagon (glp-1r) para el tratamiento de trastornos autoinmunitarios.

Info

Publication number
MX2012002463A
MX2012002463A MX2012002463A MX2012002463A MX2012002463A MX 2012002463 A MX2012002463 A MX 2012002463A MX 2012002463 A MX2012002463 A MX 2012002463A MX 2012002463 A MX2012002463 A MX 2012002463A MX 2012002463 A MX2012002463 A MX 2012002463A
Authority
MX
Mexico
Prior art keywords
glp
agonists
glucagon
peptide
receptor
Prior art date
Application number
MX2012002463A
Other languages
English (en)
Inventor
Chia-Yang Lin
Hua Long
Joyce Ching Tsu Chou
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of MX2012002463A publication Critical patent/MX2012002463A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan agonistas del receptor del péptido 1 similar a glucagón (GLP-1R) para reducir la invasión de leucocitos del sistema nervioso central en enfermedades autoinmunitarias tales como esclerosis múltiple; los agonistas de GLP-1R incluyen, por ejemplo, agonistas que se producen naturalmente tales como exendina 4, así como de péptidos del agonista de GLP-1R ligados a anticuerpos.
MX2012002463A 2009-08-27 2010-08-19 Agonistas del receptor del peptido 1 similar a glucagon (glp-1r) para el tratamiento de trastornos autoinmunitarios. MX2012002463A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23765409P 2009-08-27 2009-08-27
PCT/IB2010/053754 WO2011024110A2 (en) 2009-08-27 2010-08-19 Glucagon-like peptide-1 receptor (glp-1r) agonists for treating autoimmune disorders

Publications (1)

Publication Number Publication Date
MX2012002463A true MX2012002463A (es) 2012-03-14

Family

ID=43384669

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002463A MX2012002463A (es) 2009-08-27 2010-08-19 Agonistas del receptor del peptido 1 similar a glucagon (glp-1r) para el tratamiento de trastornos autoinmunitarios.

Country Status (13)

Country Link
US (1) US20120148586A1 (es)
EP (1) EP2470198A2 (es)
JP (1) JP2011057670A (es)
KR (1) KR20120050460A (es)
CN (1) CN102596229A (es)
AU (1) AU2010288191A1 (es)
BR (1) BR112012004043A2 (es)
CA (1) CA2769835A1 (es)
IL (1) IL217967A0 (es)
IN (1) IN2012DN00961A (es)
MX (1) MX2012002463A (es)
RU (1) RU2012106200A (es)
WO (1) WO2011024110A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012356219B2 (en) 2011-12-22 2016-03-31 Covx Technologies Ireland Limited Anti-diabetic compounds
SG11201407860PA (en) 2012-06-14 2014-12-30 Sanofi Sa Exendin-4 peptide analogues
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US20140107028A1 (en) * 2012-10-15 2014-04-17 The University Of Chicago Methods and compositions for predicting response to glp-1 analogs
MX2015008114A (es) 2012-12-21 2015-11-06 Sanofi Sa Derivados de exendina-4.
AU2014292918A1 (en) * 2013-07-25 2015-11-26 Sloan-Kettering Institute For Cancer Research Clinical multimodality-tools for pre-and intraoperative insulinoma diagnostics
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086729A1 (en) * 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080155A1 (en) * 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
AR098614A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Compuesto para el tratamiento de hipoglicemia severa
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) * 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
IL265962B2 (en) * 2016-10-10 2025-10-01 Nat Institute For Biotechnology In The Negev Ltd Non-cytotoxic adapted cells and their use
WO2018078112A1 (en) * 2016-10-27 2018-05-03 Aarhus Universitet Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
TW201833132A (zh) * 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
US20200095296A1 (en) * 2017-06-05 2020-03-26 The Trustees Of Columbia University In The City Of New York Use of peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder and tcr and/or hla immunoprofiling in neurodegenerative disease
JP7239566B2 (ja) 2017-09-22 2023-03-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
AU2019237507B2 (en) 2018-03-23 2025-04-03 Carmot Therapeutics, Inc. Modulators of G-protein coupled receptors
SMT202400344T1 (it) 2020-02-07 2024-11-15 Gasherbrum Bio Inc Agonisti di glp-1 eterociclici
IL301074A (en) * 2020-09-14 2023-05-01 Regeneron Pharma Antibody-drug conjugates comprising GLP1 peptidomimetics and their uses
AU2022271223A1 (en) 2021-05-03 2023-11-02 Carmot Therapeutics, Inc. Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
MX2023013492A (es) 2021-05-13 2024-02-29 Carmot Therapeutics Inc Moduladores de los receptores acoplados a proteinas g.
EP4490155A1 (en) 2022-03-09 2025-01-15 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN119072335A (zh) * 2022-03-11 2024-12-03 瑞泽恩制药公司 包含glp1肽模拟物的抗glp1r抗体-药物缀合物及其用途
JP2025510741A (ja) 2022-03-21 2025-04-15 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
CN119255988A (zh) 2022-04-14 2025-01-03 加舒布鲁姆生物公司 杂环glp-1激动剂
EP4562006A1 (en) 2022-07-27 2025-06-04 Carmot Therapeutics, Inc. N-heterocylic gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
EP4590698A1 (en) 2022-09-21 2025-07-30 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
JP2026501286A (ja) 2022-12-22 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
EP4638440A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AU2024311208A1 (en) 2023-06-30 2026-01-15 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AR133240A1 (es) 2023-07-13 2025-09-10 Aconcagua Bio Inc Compuestos, composiciones y métodos
TW202519220A (zh) 2023-07-13 2025-05-16 美商雅空嘉閣生物公司 化合物、組合物及方法
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
WO1991015515A1 (en) 1990-04-06 1991-10-17 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
DE69732572T2 (de) 1996-11-12 2005-12-29 Novo Nordisk A/S Verwendung von glp-1 peptiden
US6723530B1 (en) 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US6326176B1 (en) 1997-12-18 2001-12-04 The Scripps Research Institute Aldol condensations by catalytic antibodies
CA2385888A1 (en) 1999-09-27 2001-04-05 The Regents Of The University Of California Engineering antibodies that bind irreversibly
US6294374B1 (en) 1999-10-08 2001-09-25 The Scripps Research Institute Use of catalytic antibodies for synthesizing epothilone
CN1321682C (zh) * 2001-06-27 2007-06-20 前体生物药物股份有限公司 新的二肽基肽酶iv抑制剂和它们作为抗癌药的用途
EP2275117B1 (en) * 2001-07-31 2016-10-26 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
US20060275288A1 (en) * 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
CN101511868B (zh) 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CA2672750A1 (en) 2006-12-20 2008-07-03 Rinat Neuroscience Corporation Trkb agonists for treating autoimmune disorders
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US20100261637A1 (en) * 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use

Also Published As

Publication number Publication date
US20120148586A1 (en) 2012-06-14
AU2010288191A1 (en) 2012-03-01
JP2011057670A (ja) 2011-03-24
RU2012106200A (ru) 2013-10-10
CA2769835A1 (en) 2011-03-03
WO2011024110A2 (en) 2011-03-03
EP2470198A2 (en) 2012-07-04
KR20120050460A (ko) 2012-05-18
CN102596229A (zh) 2012-07-18
IL217967A0 (en) 2012-03-29
BR112012004043A2 (pt) 2019-09-24
IN2012DN00961A (es) 2015-04-10
WO2011024110A3 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
MX2012002463A (es) Agonistas del receptor del peptido 1 similar a glucagon (glp-1r) para el tratamiento de trastornos autoinmunitarios.
MY193616A (en) Gip and glp-1 co-agonist compounds
MD20170055A2 (ro) Co-agonişti ai receptorilor glucagonului şi GLP-1
MY167814A (en) Long-acting oxyntomodulin variants and methods of producing same
WO2012015975A3 (en) Glp-1 receptor agonist compounds having stabilized regions
GEP20176629B (en) Glucagon/glp-1 receptor co-agonists
MX365458B (es) Agonistas de glucagon/peptido similiar al glucagon de tipo 1 (glp-1) para el tratamiento de la obesidad.
TN2012000393A1 (en) Agonist dr5 binding polypeptides
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
BRPI0924307A8 (pt) Análogos de oxintomodulina
MX2009006794A (es) Agonistas del receptor tirosina quinasa b para el tratamiento de trastornos autoinmunes.
TN2015000053A1 (en) Fusion proteins for treating a metabolic syndrome
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
PE20151239A1 (es) Derivados de exendina-4 funcionalizada
MX2019010846A (es) Polipeptidos de il-22 y proteinas de fusion de il-22 fc y metodos de uso.
MX2014006514A (es) Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4).
MX364916B (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermadades inflamatorias oculares.
WO2009095489A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
IN2012DN02120A (es)
MX2014005351A (es) Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
MX356163B (es) Anilinas sustituidas como antagonistas de ccr(4).
WO2013063458A3 (en) Inhibiting g protein coupled receptor 6 kinase polypeptides
MX2010000979A (es) Metodos y composiciones para tratar enfermedad autoinmune.
PH12015502100A1 (en) Reducing the risk of autoimmune disease

Legal Events

Date Code Title Description
FA Abandonment or withdrawal